Synthesis and conformational analysis of a non-amidine factor Xa inhibitor that incorporates 5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine as S4 binding element

被引:60
作者
Haginoya, N
Kobayashi, S
Komoriya, S
Yoshino, T
Suzuki, M
Shimada, T
Watanabe, K
Hirokawa, Y
Furugori, T
Nagahara, T
机构
[1] Daiichi Pharmaceut Co Ltd, Med Chem Res Lab, Discovery Res Lab, Drug Metab & Physicochem Property Res Lab, Tokyo 1348630, Japan
[2] Daiichi Pharmaceut Co Ltd, New Prod Res Lab 2, Tokyo 1348630, Japan
关键词
D O I
10.1021/jm049884d
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Our exploratory study was based on the concept that a non-amidine factor Xa (fXa) inhibitor is suitable for an orally available anticoagulant. We synthesized and evaluated a series of N-(6-chloronaphthalen-2-yl)sulfonylpiperazine derivatives incorporating various fused-bicyclic rings containing an aliphatic amine expected to be S4 binding element. Among this series, 5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine type 61 displayed orally potent anti-fXa activity and evident prolongation of prothrombin time (PT) with the moderate bioavailability in rats. The X-ray crystal analysis afforded an obvious binding mode that 5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine and 6-chloronaphthalene respectively bound to S4 and S1 subsites. In this X-ray study, we discovered a novel intramolecular S-O close contact. Ab initio energy calculations of model compounds deduced that conformers with the most close S-O proximity were most stable. The Mulliken population analysis proposed that this energy profile was caused by both of electrostatic S-O affinity and N-O repulsion. The results of these calculations and X-ray analysis suggested a possibility that the restricted conformation effected the affinity to S4 subsite of fXa.
引用
收藏
页码:5167 / 5182
页数:16
相关论文
共 70 条
[61]   Substituted acrylamides as factor Xa inhibitors: Improving bioavailability by P1 modification [J].
Song, YH ;
Clizbe, L ;
Bhakta, C ;
Teng, W ;
Li, WH ;
Wong, P ;
Huang, B ;
Sinha, U ;
Park, G ;
Reed, A ;
Scarborough, RM ;
Zhu, BY .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2002, 12 (15) :2043-2046
[62]  
STEIN PD, 1994, POSTGRAD MED J, V70, pS72
[63]  
TAKAHASHI T, 1954, Pharm Bull, V2, P34
[64]  
TAKAHASHI T, 1954, Pharm Bull, V2, P196
[65]   Structure-activity relationships of penem antibiotics: Crystallographic structures and implications for their antimicrobial activities [J].
Tanaka, R ;
Oyama, Y ;
Imajo, S ;
Matsuki, S ;
Ishiguro, M .
BIOORGANIC & MEDICINAL CHEMISTRY, 1997, 5 (07) :1389-1399
[66]   THE BASIC STRENGTH OF AMINES [J].
TROTMANDICKENSON, AF .
JOURNAL OF THE CHEMICAL SOCIETY, 1949, (MAY) :1293-1297
[67]   Potent noncovalent thrombin inhibitors that utilize the unique amino acid D-dicyclohexylalanine in the P3 position. Implications on oral bioavailability and antithrombotic efficacy [J].
Tucker, TJ ;
Lumma, WC ;
Lewis, SD ;
Gardell, SJ ;
Lucas, BJ ;
Baskin, EP ;
Woltmann, R ;
Lynch, JJ ;
Lyle, EA ;
Appleby, SD ;
Chen, IW ;
Dancheck, KB ;
Vacca, JP .
JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (11) :1565-1569
[68]  
WALENGA JM, 1999, CURR OPIN CARDIOVASC, V1, P13
[69]   METHODOLOGY FOR THE FACILE AND REGIO-CONTROLLED SYNTHESIS OF INDOLES [J].
WENDER, PA ;
WHITE, AW .
TETRAHEDRON, 1983, 39 (22) :3767-3776
[70]   Factor Xa inhibitors: Recent advances in anticoagulant agents [J].
Zhu, BY ;
Scarborough, RM .
ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 35, 2000, 35 :83-102